Strategy |
Target |
Drug |
Immune checkpoint inhibitor |
Status |
Clincal trial |
Block the recruitment |
CXCR1 |
LY2510924 |
Durvalumab |
Terminated |
NCT02737072 |
|
CXCR1/CXCR2 |
SX-682 |
Nivolumab |
Recruiting |
NCT04477343 |
|
|
|
Tislelizumab |
Recruiting |
NCT05604560 |
|
CXCR4 |
BL-8040 |
Pembrolizumab |
Active, not Recruiting |
NCT02907099 |
|
|
|
|
Completed |
NCT02826486 |
|
|
|
Cemiplimab |
Recruiting |
NCT04543071 |
|
|
|
Atezolizumab |
Recruiting |
NCT03193190 |
|
|
AMD3100 |
Cemiplimab |
Completed |
NCT04177810 |
|
CXCR2/CXCR5 |
BMS-813160 |
Nivolumab |
Completed |
NCT03184870 |
|
|
|
|
Recruiting |
NCT03767582 |
|
CXCL12 |
NOX-A12 |
Pembrolizumab |
Not yet Recruiting |
NCT04901741 |
|
|
|
|
Completed |
NCT03168139 |
|
IL-8 |
BMS-986253 |
Nivolumab |
Recruiting |
NCT02451982 |
|
IL-6 |
Tocilizumab |
Ipilimumab, Nivolumab |
Terminated |
NCT04258150 |
Block polarization |
TGF-β |
LY2157299 |
Durvalumab |
Completed |
NCT02734160 |
|
|
AGEN1423 |
Balstilimab |
Not
yet recruiting |
NCT05632328 |
|
|
TGFβ peptide vaccine |
Ipilimumab |
Recruiting |
NCT05721846 |